THE potential saving of €98b (or
AU$145 billion) is creating a huge
temptation for health authorities
in Europe to adopt biosimilars
in preference to original brand
products from companies such as
Roche and AbbVie, sparking risk
fears in investors, according to a
Reuters analysis of an IMS report.
AbbVie’s Humira and Roche’s
Herceptin are both set to lose
patent protection over the next
five years which could see an
investor “cliff jump” style exit
while companies such as South
Korea’s Celltrion and large generic
drugmakers with biotech know how,
like Novartis’ generic unit
Sandoz flex their marketing muscle.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.